Form 4: Indivior CSO's Stock Vesting & Tax Sale

Indivior Pharmaceuticals' Chief Scientific Officer, Christian Heidbreder, saw 101,544 performance stock units vest, followed by a sale of 45,797 shares to cover tax obligations.

Summary

• Christian Heidbreder, Chief Scientific Officer of Indivior Pharmaceuticals, Inc., reported changes in his beneficial ownership of company common stock.
• 101,544 shares of common stock were acquired on March 3, 2026, due to the vesting of performance stock units (PSUs).
• These PSUs were granted on March 3, 2023, with performance conditions met at 76.6% of the target amount of 132,565 units.
• Following the vesting, 45,797 shares were disposed of on March 3, 2026, at a price of $31.98 per share to satisfy tax withholding obligations.
• After these transactions, Heidbreder beneficially owns 246,509 shares of Indivior common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a largely neutral event, reflecting the successful vesting of executive compensation tied to performance, which is a minor positive, balanced by a routine tax-related share disposition.

Positives

• Performance conditions for the performance stock units granted on March 3, 2023, were met at 76.6%, leading to the vesting of 101,544 shares, indicating successful achievement of set targets.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to compensation vesting and tax sales, are routine events in the pharmaceutical industry, reflecting standard executive compensation practices rather than a direct signal of company performance or strategic shifts.

Comparison to Industry Standards

• The vesting of performance stock units at 76.6% suggests that Indivior's performance metrics, against which these units were granted, were largely met, which is a common outcome for well-performing executives in the pharmaceutical sector.
• The sale of shares to cover tax obligations upon vesting is a standard practice for executives across industries, including pharmaceutical companies like Pfizer or Johnson & Johnson, and does not typically indicate a lack of confidence in the company's future.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The vesting and subsequent sale represent a routine insider transaction related to executive compensation, which is generally expected and does not typically signal a significant change in company outlook.
• Employees: This filing demonstrates the company's adherence to its executive compensation plans, which can be a positive for employee morale and retention.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the vesting of performance stock units and a subsequent sale to cover tax obligations. It does not provide new information that would fundamentally alter the investment thesis for Indivior Pharmaceuticals, Inc. The vesting at 76.6% indicates performance conditions were largely met, which is a minor positive, but the overall transaction is a standard compensation event and not a signal for a 'buy' or 'sell' decision. Therefore, a 'hold' recommendation is appropriate as this filing alone does not warrant a change in existing positions.

Keywords

Indivior, INDV, Form 4, insider transaction, stock vesting, performance stock units, executive compensation, Christian Heidbreder, Chief Scientific Officer